)
Dr. Reddy's Laboratories Ltd. on Friday announced that it has acquired the trademark rights of the breast cancer drug Primcyv from Pfizer Products
India Pvt Ltd for use in the Indian market.
Primcyv is a targeted therapy containing the active constituent palbociclib, a first-in-class CDK 4/6 inhibitor indicated in combination with an aromatase inhibitor for the first-line
treatment of adult patients with HR+, HER2 metastatic breast cancer, said a press release from the city-based drug-maker.
Since May 2022, Dr. Reddy's has been marketing the drug in collaboration with Pfizer Products India under the brandname Primcyv in India. The drug comes in the form of hard
capsules in strengths of 75 mg, 100 mg and 125 mg, it further said.
Following the trademark rights acquisition, Dr. Reddy's will manufacture the Active Pharmaceutical Ingredient (API) and finished drug at its state-of-the-art facilities approved by the United States Food and Drug Administration (USFDA).
Dr. Reddy's is amongst select companies in the world to have conducted a bioequivalence study and received tentative approval from the USFDA for palbociclib. The in-house
product will be retailed in the Indian market at a reduction of 85 per cent from the current MRP to increase affordability and access to palbociclib.
Dr. Reddy's plans to roll out a unique Patient Assistance Programme to support long-term therapy of the patients on Primcyv, it added.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
